SCHEMBL3205095

SCHEMBL3205095

Cc1ccc(B(O)O)c(C(F)(F)F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.43
SYK P43405 1/20 0.38
CA2 P00918 1/20 0.38
LPL P06858 1/20 0.38
LIPG Q9Y5X9 1/20 0.38
AR P10275 5/20 0.36
MGLL Q99685 2/20 0.34
KIF11 P52732 1/20 0.34
MAPT P10636 2/20 0.34
RAB9A P51151 2/20 0.34
TP53 P04637 1/20 0.34
AKR1C3 P42330 1/20 0.33
AKR1C2 P52895 1/20 0.33
FFAR4 Q5NUL3 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TRPA1 O75762 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29951765 1.00 SMN1; SMN2 (0.43) SMN1; SMN2SYKCA2LPLLIPG
SCHEMBL2560200 0.86 SMN1; SMN2 (0.33) SMN1; SMN2CA2LPLLIPGAR
SCHEMBL16384318 0.83 SMN1; SMN2 (0.39) SMN1; SMN2SYKCA2LPLLIPG
SCHEMBL536190 0.79 IDO1 (0.42) MGLLKMT2ATRPA1
SCHEMBL1528987 0.79 NR1I2 (0.42) ARMGLLKIF11HTT
SCHEMBL496773 0.79 CES2 (0.50) ARMGLLKIF11
SCHEMBL29953597 0.79 NR1I2 (0.42) ARMGLLKIF11HTT
SCHEMBL29349652 0.79 CES2 (0.50) ARMGLLKIF11
SCHEMBL29825643 0.79 IDO1 (0.42) MGLLKMT2ATRPA1
SCHEMBL3785258 0.78 TSHR (0.55) SMN1; SMN2ARMGLLKIF11MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250206724-A1 SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2025-06-26 US disclosed
US-20230329101-A1 Organic Light Emitting Compound And Organic Light Emitting Device Including Same P&h Tech Co., Ltd. (KR) 2023-10-12 US disclosed
WO-2023186773-A1 SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2023-10-05 WO disclosed
US-9695129-B2 Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof MERIAL INC. (US) 2017-07-04 US disclosed
EP-2784065-B1 GLYCINE REUPTAKE INHIBITOR AND USE THEREOF BEIJING MEDISAN TECHNOLOGY CO LTD (CN) 2016-10-05 EP disclosed
US-20160251317-A1 PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF MERIAL INC (US) 2016-09-01 US disclosed
EP-2673281-B1 BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTICS USES THEREOF REMPEX PHARMACEUTICALS INC (US) 2016-04-13 EP disclosed
US-9242938-B2 Glycine reuptake inhibitor and use thereof BEIJING MEDISAN TECHNOLOGY CO., LTD (CN) 2016-01-26 US disclosed
US-20150155490-A1 ORGANIC COMPOUNDS AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME LG DISPLAY CO., LTD. (KR) 2015-06-04 US disclosed
US-20150133497-A1 GLYCINE REUPTAKE INHIBITOR AND USE THEREOF BEIJING MEDISAN TECHNOLOGY CO., LTD. (CN) 2015-05-14 US disclosed
US-9000187-B2 Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof MERIAL, INC. (US) 2015-04-07 US disclosed
US-8933018-B2 Boron containing polybasic bacterial efflux pump inhibitors and therapeutic uses thereof REMPEX PHARMACEUTICALS, INC. (US) 2015-01-13 US disclosed
US-8901145-B2 Aminopyrimidine kinase inhibitors Jasco Pharmaceuticals, LLC (US) 2014-12-02 US disclosed
EP-2784065-A1 GLYCINE REUPTAKE INHIBITOR AND USE THEREOF Beijing Medisan Technology Co. Ltd. (CN) 2014-10-01 EP disclosed
US-20130281392-A1 PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF MERIAL LIMITED (US) 2013-10-24 US disclosed
US-20120270892-A1 Aminopyrimidine Kinase Inhibitors Jasco Pharmaceuticals, LLC (US) 2012-10-25 US disclosed
US-20100035871-A1 BENZOXAZINE DERIVATIVES AND USES THEREOF WYETH 2010-02-11 US disclosed
WO-2009111501-A1 DERIVATIVES OF IMIDAZO [4, 5-D] PYRIDAZINE AND THEIR USE AS ANTI-VIRAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-09-11 WO disclosed
US-20090226398-A1 ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE GENELABS TECHNOLOGIES, INC. 2009-09-10 US disclosed
WO-2008052075-A2 BENZOXAZINE DERIVATIVES AND USES THEREOF WYETH (US) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150133497-A1 GLYCINE REUPTAKE INHIBITOR AND USE THEREOF SLC6A2, SLC6A5, SLC6A4 SMN1; SMN2 4049/4885SYK 4511/4885CA2 1104/4885
US-20250206724-A1 SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS CDK1, CDK11A, CDK3 SMN1; SMN2 2939/4885SYK 2053/4885CA2 3967/4885
US-20160251317-A1 PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF LIPC, CYP3A43, CYP51A1 SMN1; SMN2 4525/4885SYK 1975/4885CA2 1466/4885
US-20100035871-A1 BENZOXAZINE DERIVATIVES AND USES THEREOF HTR2C, HTR5A, NPY1R SMN1; SMN2 2935/4885SYK 1167/4885CA2 3005/4885
US-20120270892-A1 Aminopyrimidine Kinase Inhibitors PIM1, PIM2, PIM3 SMN1; SMN2 3597/4885SYK 1038/4885CA2 1537/4885
US-20130281392-A1 PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF LIPC, CYP3A43, CYP51A1 SMN1; SMN2 4525/4885SYK 1975/4885CA2 1466/4885
US-20230329101-A1 Organic Light Emitting Compound And Organic Light Emitting Device Including Same ORMDL3, OR10J3, ORC3 SMN1; SMN2 3094/4885SYK 3161/4885CA2 3634/4885
US-20090226398-A1 ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE MAVS, SARS1, HAVCR2 SMN1; SMN2 396/4885SYK 3986/4885CA2 1373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.